[go: up one dir, main page]

NO20076241L - Terapier for vaskulaere sykdommer - Google Patents

Terapier for vaskulaere sykdommer

Info

Publication number
NO20076241L
NO20076241L NO20076241A NO20076241A NO20076241L NO 20076241 L NO20076241 L NO 20076241L NO 20076241 A NO20076241 A NO 20076241A NO 20076241 A NO20076241 A NO 20076241A NO 20076241 L NO20076241 L NO 20076241L
Authority
NO
Norway
Prior art keywords
vascular disease
disease therapies
vascular
methods
therapies
Prior art date
Application number
NO20076241A
Other languages
English (en)
Inventor
David Y Liu
Ingrid Langsetmo Parobok
Christopher T Jacob
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Publication of NO20076241L publication Critical patent/NO20076241L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Den foreliggende oppfinnelsen angår fremgangsmåter og midler for å behandle svekket vaskulær- og hjertefunksjon. Det er også tilveiebrakt fremgangsmåter og midler for å behandle forskjellige fysiologiske og patologiske trekk som er assosiert med vaskulærdysfunksjon og hjertedysfunksjon.
NO20076241A 2005-05-05 2007-12-04 Terapier for vaskulaere sykdommer NO20076241L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67849505P 2005-05-05 2005-05-05
US69095705P 2005-06-15 2005-06-15
US73443305P 2005-11-07 2005-11-07
PCT/US2006/017759 WO2006122046A2 (en) 2005-05-05 2006-05-05 Vascular disease therapies

Publications (1)

Publication Number Publication Date
NO20076241L true NO20076241L (no) 2008-02-04

Family

ID=36778299

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20076121A NO20076121L (no) 2005-05-05 2007-11-27 Behandlinger for kardiovaskulaer sykdom
NO20076241A NO20076241L (no) 2005-05-05 2007-12-04 Terapier for vaskulaere sykdommer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20076121A NO20076121L (no) 2005-05-05 2007-11-27 Behandlinger for kardiovaskulaer sykdom

Country Status (10)

Country Link
US (3) US8088381B2 (no)
EP (2) EP1885756A2 (no)
JP (2) JP2008540456A (no)
AU (2) AU2006244147A1 (no)
CA (2) CA2607044A1 (no)
IL (2) IL187113A (no)
MX (2) MX2007013819A (no)
NO (2) NO20076121L (no)
NZ (1) NZ563493A (no)
WO (2) WO2006122046A2 (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007098065A2 (en) * 2006-02-17 2007-08-30 The United States Of America As Represented By The Department Of Veterans Affairs Human sodium channel isoforms
US20080075666A1 (en) * 2006-08-25 2008-03-27 Dudley Samuel C Jr Methods and compositions for treating diastolic dysfunction
US9114133B2 (en) 2006-08-25 2015-08-25 U.S. Dept. Of Veterans Affairs Method of improving diastolic dysfunction
US9220720B2 (en) 2007-10-18 2015-12-29 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy
US9211301B2 (en) 2007-10-18 2015-12-15 U.S. Department Of Veterans Affairs Method for ameliorating or preventing arrhythmic risk associated with cardiomyopathy by improving conduction velocity
US9050350B2 (en) 2007-10-18 2015-06-09 U.S. Department Of Veterans Affairs Method for modulating or controlling connexin 43(Cx43) level of a cell and reducing arrhythmic risk
US9114151B2 (en) * 2007-10-18 2015-08-25 The United States Of America Dept. Of Veterans Affairs Method for modulating or controlling sodium channel current by reactive oxygen species (ROS) originating from mitochondria
CA2733262C (en) 2008-08-25 2019-12-10 Excaliard Pharmaceuticals Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
AU2009294362A1 (en) * 2008-09-18 2010-03-25 Universitetet I Oslo Use of CTGF as a cardioprotectant
US20110262398A1 (en) * 2010-04-21 2011-10-27 University Of Illinois Cardiac treatment using anti-fibrotic agents
KR101249041B1 (ko) 2010-04-28 2013-03-29 포항공과대학교 산학협력단 결합조직 성장인자를 이용한 약학적 조성물
TWI593416B (zh) 2011-02-02 2017-08-01 艾克厘德製藥公司 利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法
DE102012103096A1 (de) * 2012-04-11 2013-10-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Prophylaxe und Behandlung einer Gefäßkalzifizierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
US7384634B2 (en) * 1991-08-30 2008-06-10 University Of South Florida Connective tissue growth factor
JPH11180895A (ja) 1997-09-12 1999-07-06 Masaharu Takigawa 血管新生阻害剤
WO1999033878A1 (en) * 1997-12-25 1999-07-08 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
WO2000002450A1 (en) 1998-07-08 2000-01-20 Fibrogen, Inc. Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
MXPA01005949A (es) 1998-12-14 2002-09-18 Univ Miami Fragmentos de factor de crecimiento de tejido conectivo y metodos y usos de los mismos.
US7115390B1 (en) * 1998-12-14 2006-10-03 Fibrogen, Inc. Connective tissue growth factor fragments and methods and uses thereof
JP2004502644A (ja) * 2000-03-09 2004-01-29 ジェンザイム、コーポレーション 腎機能の喪失を治療または予防するためのＴＧＦ−β拮抗薬の使用
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2002366641A1 (en) 2001-12-11 2003-06-23 Fibrogen, Inc. Methods for inhibiting ocular processes
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
WO2005077413A1 (en) 2004-02-11 2005-08-25 Fibrogen, Inc. Ctgf as target for the therapy of diabetic nephropathy

Also Published As

Publication number Publication date
EP1885756A2 (en) 2008-02-13
MX2007013834A (es) 2008-02-05
US20060281667A1 (en) 2006-12-14
IL187113A0 (en) 2008-02-09
IL187113A (en) 2011-06-30
EP1891109A1 (en) 2008-02-27
JP5068253B2 (ja) 2012-11-07
NO20076121L (no) 2008-02-04
CA2607044A1 (en) 2006-11-16
JP2008540456A (ja) 2008-11-20
US8088381B2 (en) 2012-01-03
WO2006122046A3 (en) 2007-05-31
NZ563493A (en) 2010-10-29
US20060281668A1 (en) 2006-12-14
AU2006244147A1 (en) 2006-11-16
US20120039882A1 (en) 2012-02-16
IL187115A0 (en) 2008-02-09
CA2606778A1 (en) 2006-11-16
JP2008540457A (ja) 2008-11-20
WO2006122046A2 (en) 2006-11-16
MX2007013819A (es) 2008-02-05
WO2006122047A1 (en) 2006-11-16
AU2006244148A1 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
NO20076241L (no) Terapier for vaskulaere sykdommer
NO20083002L (no) Fremgangsmate for anvendelse av CD40-bindende forbindelser
DK1472541T3 (da) Afbildningsmidler og metoder til at afbilde NAALADase og PSMA
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
TNSN05300A1 (en) Treatment with anti-vegf antibodies
EA200802213A1 (ru) Способы лечения заболеваний крови
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
NO20071860L (no) Forbindelser, sammensetninger og fremgangsmater for a hemme alpha-synukleintoksisitet
NO20060027L (no) Antistoffer mot bindevevsvekstfaktor
DE602006010476D1 (de) Implantierbares Herzdiagnosesystem
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
NO20034590D0 (no) Fremgangsmåter for behandling av vaskul¶r sykdom
EA200700058A1 (ru) Соединения, композиции и способы их использования
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
GB0423356D0 (en) Therapeutic agents
TW200722083A (en) Combinations and methods of using an indolinone compound
WO2006127900A3 (en) Tl1a in the treatment of disease
DK1765859T3 (da) Annexiner, derivater deraf og annexin-cys varianter samt terapeutiske og diagnostiske anvendelser deraf
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
NO20076405L (no) Anvendelse av 24-nor-UDCA
GB0416508D0 (en) Therapeutic agents
EA200400399A1 (ru) Способы лечения легочных заболеваний
IL190496A0 (en) Methods for reducing blood pressure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application